HEPA — Hepion Pharmaceuticals Share Price
- $5.92m
- -$5.50m
- 17
- 33
- 18
- 12
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.95 | ||
Price to Tang. Book | 0.95 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -301.31% | ||
Return on Equity | -186.61% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.
Directors
- Gary Jacob NEC (74)
- Robert Foster CEO (62)
- John Cavan CFO (62)
- Todd Hobbs OTH
- Timothy Block IND (66)
- John Brancaccio IND (73)
- Arnold Lippa IND (74)
- Petrus Wijngaard IND (58)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- May 15th, 2013
- Public Since
- February 7th, 2014
- No. of Shareholders
- 344
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 5,473,126
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- 399 Thornall St, EDISON, 08837-2236
- Web
- https://hepionpharma.com/
- Phone
- +1 7329024000
- Auditors
- Grassi & Co., CPAs, P.C.
Upcoming Events for HEPA
Q3 2024 Hepion Pharmaceuticals Inc Earnings Release
Similar to HEPA
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
As of Today at 21:06 UTC, shares in Hepion Pharmaceuticals are trading at $1.02. This share price information is delayed by 15 minutes.
Shares in Hepion Pharmaceuticals last closed at $1.02 and the price had moved by -91.56% over the past 365 days. In terms of relative price strength the Hepion Pharmaceuticals share price has underperformed the S&P500 Index by -93.28% over the past year.
The overall consensus recommendation for Hepion Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Hepion Pharmaceuticals does not currently pay a dividend.
Hepion Pharmaceuticals does not currently pay a dividend.
Hepion Pharmaceuticals does not currently pay a dividend.
To buy shares in Hepion Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.02, shares in Hepion Pharmaceuticals had a market capitalisation of $5.56m.
Here are the trading details for Hepion Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: HEPA
Based on an overall assessment of its quality, value and momentum Hepion Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Hepion Pharmaceuticals is $30.00. That is 2855.67% above the last closing price of $1.02.
Analysts covering Hepion Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$11.43 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Hepion Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -73.13%.
As of the last closing price of $1.02, shares in Hepion Pharmaceuticals were trading -64.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Hepion Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Hepion Pharmaceuticals' management team is headed by:
- Gary Jacob - NEC
- Robert Foster - CEO
- John Cavan - CFO
- Todd Hobbs - OTH
- Timothy Block - IND
- John Brancaccio - IND
- Arnold Lippa - IND
- Petrus Wijngaard - IND